BRPI0811499A2 - Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. - Google Patents

Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Info

Publication number
BRPI0811499A2
BRPI0811499A2 BRPI0811499-4A2A BRPI0811499A BRPI0811499A2 BR PI0811499 A2 BRPI0811499 A2 BR PI0811499A2 BR PI0811499 A BRPI0811499 A BR PI0811499A BR PI0811499 A2 BRPI0811499 A2 BR PI0811499A2
Authority
BR
Brazil
Prior art keywords
antigen
viral virus
purifying
preparing
methods
Prior art date
Application number
BRPI0811499-4A2A
Other languages
English (en)
Inventor
Manfred Reiter
Leopold Grillberger
Wolfgang Mundt
Artur Mitterer
Horst Schafhauser
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811499(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of BRPI0811499A2 publication Critical patent/BRPI0811499A2/pt
Publication of BRPI0811499B1 publication Critical patent/BRPI0811499B1/pt
Publication of BRPI0811499B8 publication Critical patent/BRPI0811499B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
BRPI0811499A 2007-05-04 2008-04-30 métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. BRPI0811499B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04
US60/927692 2007-05-04
PCT/EP2008/003531 WO2008135229A2 (en) 2007-05-04 2008-04-30 Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Publications (3)

Publication Number Publication Date
BRPI0811499A2 true BRPI0811499A2 (pt) 2014-10-14
BRPI0811499B1 BRPI0811499B1 (pt) 2019-06-04
BRPI0811499B8 BRPI0811499B8 (pt) 2021-05-25

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811499A BRPI0811499B8 (pt) 2007-05-04 2008-04-30 métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Country Status (18)

Country Link
US (4) US20100239609A1 (pt)
EP (1) EP2155864B1 (pt)
JP (2) JP5745717B2 (pt)
KR (4) KR101744430B1 (pt)
CN (2) CN101688187A (pt)
AR (1) AR066449A1 (pt)
AU (1) AU2008248904B2 (pt)
BR (1) BRPI0811499B8 (pt)
CA (1) CA2687119C (pt)
CL (1) CL2008001294A1 (pt)
HK (2) HK1138318A1 (pt)
IL (1) IL201898A (pt)
MX (1) MX2009011897A (pt)
PE (1) PE20090284A1 (pt)
RU (1) RU2503719C2 (pt)
TW (1) TWI472620B (pt)
WO (1) WO2008135229A2 (pt)
ZA (1) ZA200907743B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101744430B1 (ko) * 2007-05-04 2017-06-20 백스터 인터내셔널 인코포레이티드 바이러스 정제를 위한 연속 초원심분리용 당 용액의 제조
US20110293660A1 (en) * 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
US20170369854A1 (en) 2014-12-16 2017-12-28 Glaxosmithkline Biologicals Sa A method for a large scale virus purification
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
ES2948849T3 (es) * 2016-11-04 2023-09-20 Takeda Pharmaceuticals Co Métodos de purificación de virus adenoasociado
EP3589956A1 (en) 2017-03-03 2020-01-08 Baxalta Incorporated Methods for determining potency of adeno-associated virus preparations
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法
EP4330270A2 (en) 2021-04-30 2024-03-06 Takeda Pharmaceutical Company Limited Aav8 capsid variants with enhanced liver targeting
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
CA3234817A1 (en) * 2021-10-12 2023-04-20 Remo MOOMIAIE Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
DE2964132D1 (en) * 1978-05-08 1983-01-05 Merck & Co Inc A process for the direct extraction of small size particles of up to 50 nm from a protein aceous liquid
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
ATE534666T1 (de) * 2003-04-01 2011-12-15 Inst Nat Sante Rech Med Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
KR101744430B1 (ko) * 2007-05-04 2017-06-20 백스터 인터내셔널 인코포레이티드 바이러스 정제를 위한 연속 초원심분리용 당 용액의 제조

Also Published As

Publication number Publication date
KR101744430B1 (ko) 2017-06-20
KR20150082676A (ko) 2015-07-15
RU2503719C2 (ru) 2014-01-10
JP2015061538A (ja) 2015-04-02
KR101998537B1 (ko) 2019-07-09
WO2008135229A2 (en) 2008-11-13
US20100239609A1 (en) 2010-09-23
TW200914615A (en) 2009-04-01
AR066449A1 (es) 2009-08-19
US20160060603A1 (en) 2016-03-03
AU2008248904A1 (en) 2008-11-13
CN101688187A (zh) 2010-03-31
KR101873891B1 (ko) 2018-07-04
KR20170065671A (ko) 2017-06-13
JP2010525798A (ja) 2010-07-29
HK1138318A1 (en) 2010-08-20
BRPI0811499B1 (pt) 2019-06-04
PE20090284A1 (es) 2009-03-17
IL201898A0 (en) 2011-08-01
KR20180077305A (ko) 2018-07-06
ZA200907743B (en) 2010-09-29
US20080274138A1 (en) 2008-11-06
US20170369853A1 (en) 2017-12-28
EP2155864A2 (en) 2010-02-24
JP5745717B2 (ja) 2015-07-08
BRPI0811499B8 (pt) 2021-05-25
US9732327B2 (en) 2017-08-15
CL2008001294A1 (es) 2009-03-06
AU2008248904B2 (en) 2014-10-09
KR20100017594A (ko) 2010-02-16
WO2008135229A3 (en) 2008-12-31
TWI472620B (zh) 2015-02-11
RU2009144980A (ru) 2011-06-10
JP6031082B2 (ja) 2016-11-24
HK1211320A1 (en) 2016-05-20
IL201898A (en) 2013-11-28
MX2009011897A (es) 2010-02-04
CA2687119A1 (en) 2008-11-13
EP2155864B1 (en) 2013-07-17
CA2687119C (en) 2021-06-08
US8969533B2 (en) 2015-03-03
CN104694489A (zh) 2015-06-10

Similar Documents

Publication Publication Date Title
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
EP1984405A4 (en) INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
BRPI0716536A2 (pt) produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
BRPI1014322A2 (pt) Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
ZA200800505B (en) Modified influenza virus for monitoring and improving vaccine efficiency
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
DK2049559T3 (da) Forbedrede HPV vacciner
IL198466A (en) Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
WO2014052378A3 (en) Subunit immersion vaccines for fish
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
BRPI0807597A2 (pt) Composição farmacêutica, e, método para tratar infecção por vírus da influenza
IL200588A0 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
BRPI0818354A2 (pt) vacina preventiva do hiv baseada em anticorpos específicos para o hiv
BRPI0810865A2 (pt) antígenos de tripanossoma, composições vacinais, e métodos relacionados
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
EA201001045A1 (ru) Модифицированный вирус гриппа
BRPI0814300A2 (pt) Composto, composição farmacêutica, e, método para tratar uma infecção viral
ZA200809056B (en) Influenza virus vaccine
BRPI0919485A2 (pt) vacinas, antígenos, composições de plasmodium e métodos
HK1219052A1 (zh) 針對典型性豬瘟病毒的嵌合疫苗抗原
AP2011005954A0 (en) Vaccine against African horse sickness virus.
WO2007082734A3 (en) Influenza vaccine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)